JPMorgan Chase & Co. Acquires 3,635 Shares of Xencor, Inc. (NASDAQ:XNCR)

JPMorgan Chase & Co. grew its holdings in Xencor, Inc. (NASDAQ:XNCR) by 2.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 130,354 shares of the biopharmaceutical company’s stock after purchasing an additional 3,635 shares during the period. JPMorgan Chase & Co. owned approximately 0.19% of Xencor worth $2,621,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. raised its holdings in Xencor by 8.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 949 shares during the period. KBC Group NV raised its stake in shares of Xencor by 63.5% during the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,213 shares during the period. Point72 DIFC Ltd lifted its holdings in Xencor by 10.9% during the 3rd quarter. Point72 DIFC Ltd now owns 13,511 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 1,333 shares in the last quarter. Inspire Investing LLC boosted its stake in Xencor by 10.1% in the 3rd quarter. Inspire Investing LLC now owns 20,530 shares of the biopharmaceutical company’s stock worth $413,000 after purchasing an additional 1,887 shares during the period. Finally, Quarry LP purchased a new position in Xencor during the 2nd quarter valued at about $36,000.

Xencor Stock Performance

NASDAQ:XNCR opened at $19.24 on Tuesday. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -6.01 and a beta of 0.72. The business has a 50 day moving average of $23.82 and a 200 day moving average of $21.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $27.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. During the same period in the previous year, the business posted ($0.40) EPS. The business’s quarterly revenue was down 81.9% on a year-over-year basis. On average, sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company’s stock, valued at approximately $4,698,441.92. The trade was a 25.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bassil I. Dahiyat sold 49,278 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $24.07, for a total value of $1,186,121.46. Following the sale, the chief executive officer now owns 352,615 shares of the company’s stock, valued at $8,487,443.05. This represents a 12.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 136,050 shares of company stock valued at $3,277,609 over the last three months. Insiders own 5.23% of the company’s stock.

Wall Street Analyst Weigh In

XNCR has been the topic of a number of recent analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Royal Bank of Canada increased their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Wells Fargo & Company started coverage on shares of Xencor in a research report on Thursday, December 12th. They set an “overweight” rating and a $37.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $36.56.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.